Shots:

• The company initiates a confirmatory P-III (LAGOON) trial to evaluate lurbinectedin monothx. or lurbinectedin + irinotecan vs topotecan or irinotecan in a ratio (1:1:1) in 705 patients with relapsed SCLC whose disease has progressed following prior Pt-containing CT with/out anti-PD-1 or anti-PD-L1 agents at 100+ sites mainly in North America & EU
• The 1EP of the trial is to measure OS & 2EP is PFS in patients with SCLC. Additionally, Jazz holds the commercial rights for Zepzelca in North America
• Zepzelca received US FDA approval in June 2020 for metastatic SCLC. The trial will be used as a registrational trial with the EMA for seeking marketing authorization in the EU

Ref: PR Newswire | Image: Jazz